iBxIn Biopharma

iBxIn Biopharma is a Suzhou-based biotechnology company specializing in the development of next-generation multi-specific antibodies and antibody-drug conjugates (ADCs). Founded in 2021 by Dr. Lin Sun, the company leverages its proprietary platform to design complex biologics that address unmet needs in oncology and immunology. Its lead asset, IBX-101, is a multi-specific antibody currently being developed for the treatment of hematological malignancies such as multiple myeloma. iBxIn is backed by prominent venture capital firms including Sherpa Healthcare Partners and GL Ventures. The company is positioned as an emerging innovator in the Chinese biologics sector, focusing on high-affinity, multi-functional molecules to overcome resistance in cancer therapy.